Shivali Justa

Shivali Justa

Auto-generated profile, based on publicly available information

Shivali Justa

Department of Immunopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SJShivali Justa
Shivali Justa
XZXiaoqun Zhou
Xiaoqun Zhou
SSSujata Sarkar
Sujata Sarkar
IL-22 is elevated in patients with inflammatory arthritis and correlates with disease activity. IL-22 deficient mice have reduced incidence of arthritis. Recombinant IL-22 restrains progression of arthritis via increase in IL-10 responses when administered prior to onset of arthritis. These findings imply a possible dual role of IL-22 in inflammatory arthritis depending on the phase of arthritis. Experiments outlined here were designed to elucidate the contribution of endogenous IL-22 before and after the onset of arthritis. Collagen induced arthritis (CIA) was induced in DBA1 or IFN-γ deficient mice following immunization with collagen and complete Freund's adjuvant. Anti-IL-22 antibody or isotype control were administered prior to or after onset of arthritis and disease progression assessed by clinical scoring and histopathology. IL-22, IL-17 and IFN-γ responses were measured by ELISA and flowcytometry. Anti-collagen antibody responses were analyzed by ELISA. Expression of IL-22R1 in CD4+ cells was elucidated by flowcytometry and real time PCR. Collagen specific IL-22 responses were expanded during arthritis and IL-22 producing cells were discrete from IL-17 or IFN-γ producing cells. Neutralization of IL-22 after onset of arthritis resulted in significant increase in Th1 responses and significantly reduced severity of arthritis. CD4+ cells from arthritic mice showed increased surface expression of IL-22R1. In vitro, CD4+T cells cultured with antigen presenting cells in the presence or absence of IL-22 suppressed or induced IFN-γ, respectively. The protective effect of anti-IL-22 was reversed in IFN-γ deficient mice. Moreover, administration of anti-IL-22 prior to onset of arthritis augmented arthritis severity. We show for the first time that IL-22 plays a dual role: protective prior to the onset of arthritis and pathogenic after onset of arthritis. The pathogenic effect of IL-22 is dependent on suppression of IFN-γ responses. IL-17 responses remained unchanged with the administration of anti-IL22 antibody. IL-22R1 is upregulated on CD4+T cells during arthritis and regulates IFN-γ in T cells.

24 July 2014 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
SSS Sarkar
S Sarkar
SJS Justa
S Justa
MBM Brucks
M Brucks
JEJ Endres
J Endres
DFD A Fox
D A Fox
SBS R Bommireddy
S R Bommireddy
Summary: Interleukin (IL)-17 plays a critical role in inflammation. Most studies to date have elucidated the inflammatory role of IL-17A, often referred to as IL-17. IL-17F is a member of the IL-17 family bearing 50% homology to IL-17A and can also be present as heterodimer IL-17AF. This study elucidates the distribution and contribution of IL-17A, F and AF in inflammatory arthritis. Neutralizing antibody to IL-17A alone or IL-17F alone or in combination was utilized in the mouse collagen-induced arthritis (CIA) model to elucidate the contribution of each subtype in mediating inflammation. IL-17A, F and AF were all increased during inflammatory arthritis. Neutralization of IL-17A reduced the severity of arthritis, neutralization of IL-17A+IL-17F had the same effect as neutralizing IL-17A, while neutralization of IL-17F had no effect. Moreover, significantly higher levels of IL-17A and IL-17F were detected in peripheral blood mononuclear cells (PBMC) from patients with rheumatoid arthritis (RA) in comparison to patients with osteoarthritis (OA). IL-17A and AF were detected in synovial fluid mononuclear cells (SFMC) in RA and OA, with IL-17A being significantly higher in RA patients. Enriched CD3+ T cells from RA PBMCs produced singnificantly high levels of IL-17A and IL-17AF in comparison to OA peripheral blood CD3+ T cells. IL-17A, F and AF were undetectable in T cells from SFMCs from RA and OA. While IL-17A, F, and AF were all induced during CIA, IL-17A played a dominant role. Furthermore, production of IL-17A, and not IL-17F or IL-17AF, was elevated in PBMCs, SFMCs and enriched peripheral blood CD3+ T in RA.

17 January 2013 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
SSSujata Sarkar
Sujata Sarkar
XZXiaoqun Zhou
Xiaoqun Zhou
SJShivali Justa
Shivali Justa
SBSwaroopa Rani Bommireddy
Swaroopa Rani Bommireddy
Objective The mechanism of action of interleukin‐ 22 (IL‐22) in inflammatory arthritis remains unknown. IL‐22–deficient mice exhibit an intact humoral and cellular immune response to collagen and yet have a reduced incidence of collagen‐induced arthritis (CIA). Further, administration of anti–IL‐22 does not reduce the severity of clinical arthritis but rather improves only certain aspects of joint inflammation as assessed histologically. This study was undertaken to investigate the mechanism of action and role of systemic IL‐22 in modulating target organ inflammation. Methods CIA was induced in DBA mice by immunization with collagen and Freund's complete adjuvant. Expression of IL‐22 and its receptor (IL‐22R) in lymphoid organ and target tissues was determined during various phases of arthritis. The effector functions of IL‐22 on induction/regulation of various cytokines in in vitro restimulation cultures were analyzed by enzyme‐linked immunosorbent assay (ELISA). Recombinant IL‐22 with or without anti–IL‐10 antibody was administered to mice following immunization with collagen and prior to the onset of arthritis, and the severity of arthritis was evaluated by clinical scoring and histopathologic assessment. Anticollagen antibodies in mouse sera were analyzed by ELISA. Results IL‐22 and IL‐22R were up‐regulated in lymphoid organs and joints during the course of arthritis. IL‐22 augmented IL‐10, IL‐17, and IL‐6 in lymphoid tissues in vitro. Administration of recombinant IL‐22 was associated with an increase in IL‐10 levels in vivo and a significant reduction in the progression of arthritis severity. Anti–IL‐10 antibody treatment was associated with the abrogation of this protective effect of IL‐22. Conclusion Our data demonstrate, for the first time, that IL‐22 has a protective role in inflammatory arthritis.

27 September 2010 in Transplantation
Verified
Journal Article
Closed access
SJShivali Justa
Shivali Justa
RMRanjana Walker Minz
Ranjana Walker Minz
MMMukut Minz
Mukut Minz
ASAshish Sharma
Ashish Sharma
NPNeelam Pasricha
Neelam Pasricha
VSVinay K. Sakhuja
Vinay K. Sakhuja
Background. Hepatitis C virus (HCV) infection is prevalent among renal transplant recipients. Methods. Twenty-five recipients of living donor renal transplantation with HCV (group I) and without HCV (group II) were serially monitored at three time points, that is, pretransplant, day 10, and 6 months posttransplant. Phenotypic characterization of T-cell subsets and natural killer cells was performed by flow cytometric immunophenotyping. Cytometric bead array immunoassay was used to simultaneously measure six cytokines (interleukin [IL]-2, IL-4, IL-5, IL-10, tumor necrosis factor-α, and interferon-γ) from phytohemagglutin-stimulated culture supernatants, and transforming growth factor (TGF)-β1 levels were determined by ELISA. Real-time polymerase chain reaction method was used to determine the serum viral load among group I patients at three time points. Results. Group I patients on day 10 posttransplant showed a significant increase in T cells subsets with reduced interferon-γ and increased TGF-β1 levels. A significantly increased CD8+ T cells and TGF-β levels were seen at 6-month posttransplant among group I patients. Multivariate linear regression analysis showed TGF-β and tumor necrosis factor-α as the most significant predictors affecting early (day 10) and late (6 months) posttransplant viral load, respectively. Conclusion. After an initial increase in the viral load immediately posttransplantation, there is a reduction in viral load. A concomitant timed dissection of the immune response shows a complex interactive environment in which, despite immunosuppression, not only the antiviral immune response persists but the virus is also able to modulate the host immune response for its survival. Per se, HCV does not adversely affect the allograft or patient outcome in this case–control study.

1 November 2010 in Transplantation Proceedings
Verified
Journal Article
Closed access
SJS. Justa
S. Justa
RMRanjana Walker Minz
Ranjana Walker Minz
MMM. Minz
M. Minz
ASA. Sharma
A. Sharma
SAS. Anand
S. Anand
VSV.K. Sakhuja
V.K. Sakhuja

1 January 2015 in Biomarker Insights
Verified
Journal Article
Open access
SJShivali Justa
Shivali Justa
RMRanjana Walker Minz
Ranjana Walker Minz
SAShashi Anand
Shashi Anand
MMMukut Minz
Mukut Minz
Background: The role of neopterin as a marker of cell-mediated immunity for immunological monitoring after transplantation is of great potential interest. Neopterin levels among hepatitis C virus (HCV)-positive recipients of living-donor renal transplantation (LDRT) have not been previously described. Methods: Twenty-two HCV-positive (group I) and 10 HCV-negative (group II) recipients of LDRT were serially monitored for serum neopterin levels by enzyme-linked immunosorbent assay (ELISA). Group I patients were monitored thrice, ie, before transplantation, day 10, and 6 months post transplantation, while group II patients were monitored twice (day 10 and 6 months post transplantation). Peripheral blood T-lymphocyte subsets (CD3, CD4, CD8, CD4 + CD25 + , CD 16+56 ) and Thl/Th2 cytokines were monitored concomitantly by flow cytometry. Results: Ten days post transplantation, there was a significant increase in neopterin and neopterin/creatnine levels among group I patients. There was a positive correlation between activated T-lymphocyte (CD4 + CD25 + ) and neopterin early post transplantation (day 10). Th2 cytokines IL-10 and IL-5 showed a positive correlation with neopterin levels on day 10 and 6 months post transplantation, respectively. Neopterin levels did not show association with either HCV viral load or allograft rejection among our study cohort. Conclusion: Increased monocyte/macrophage activation with elevated serum neopterin was detected among group I patients on day 10 post transplantation, but it could not predict rejection. It appears that IL-10 either from a regulatory or nonregulatory source helps in the maintenance of stable graft early post transplantation. Further, it would be of interest to assess the role of neopterin in chronic allograft nephropathy and long-term graft outcome.